Positions

Overview

  • Dr. Arnab Basu is an academic genitourinary oncologist focusing in the care of patients with Kidney Cancer & Bladder Cancer. Dr. Basu is experienced in the use of immunotherapy and targeted therapies in these diseases and has performed research in resistance mechanisms to immunotherapy. Dr. Basu is developing translational research programs in the genitourinary malignancies at UAB. In addition to kidney and bladder cancer , he also specializes in testicular, adrenal and prostate cancers.

    Dr. Basu originally obtained his medical degree from the Medical College, Kolkata, the oldest medical school in Asia. He then completed a fellowship at the Indian Council of Medical Research and a Masters in Epidemiology and Biostatistical Methods in Clinical Research from the Johns Hopkins University in Baltimore , Maryland. He then completed his Internal Medicine training at the Johns Hopkins University & Sinai Hospital of Baltimore program. Dr. Basu also has fellowship training from the University of Southern California and the Cleveland Clinic Foundation where he focused on the care of patients with genitourinary malignancies under the mentorship of Drs. Brian Rini and Dr. Petros Grivas.


    Following his Training , Dr. Basu has joined UAB as a Associate Scientist with the Comprehensive Cancer Center and a Tenure Track Assistant Professor at the UAB School of Medicine, where he is developing novel assays for the detection of resistance mechanisms to immunotherapy and mouse models for validating therapies in kidney cancer. Dr. Basu's research interests are in developing novel agents for Kidney and Bladder Cancer and to improve immunotherapies in these diseases.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional CohortFrontiers in Oncology.  10. 2020
    2020 Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have?European urology focus.  6:623-626. 2020
    2019 Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancerBMJ Case Reports.  12. 2019
    2019 Association of PD-L1, PD-L2, and immune response markers in matched renal clear cell carcinoma primary and metastatic tissue specimensAmerican Journal of Clinical Pathology.  151:217-225. 2019
    2019 The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscapeTranslational cancer research.  8:S130-S132. 2019
    2018 Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patientsPLoS ONE.  13. 2018
    2016 Primary proximal epithelioid sarcoma of the lung successfully treated with pneumonectomy and adjuvant chemotherapyBMJ Case Reports.  2016. 2016
    2016 Type 4 Hiatal HerniaAmerican Journal of the Medical Sciences.  351:e5. 2016
    2013 Palliative care in low- and medium-resource countries 2013

    Book

    Year Title Altmetric
    2014 Global Perspectives on Cancer Incidence, Care, and Experience 2014

    Chapter

    Year Title Altmetric
    2019 Targeting Mutant RAS 2019

    Education And Training

  • Master of Public Health, Johns Hopkins University 2010
  • Bachelor of Medicine & Surgery (MBBS), University of Calcutta 2008
  • Full Name

  • Arnab Basu